高翔宇，青年北京学者、研究员、副主任医师、副教授、博士生导师。北京大学肿瘤医院暨北京市肿瘤防治研究所胃肠肿瘤中心、消化系肿瘤整合防治全国重点实验室、癌症整合组学前沿科学中心、恶性肿瘤转化研究北京市重点实验室、北京大学临床医学高等研究院。北京大学、Cardiff University双博士学位（M.D., Ph.D.）。主要临床方向：基于外科的胃癌及肠癌围术期个体化诊疗。研究方向：围术期综合治疗前后免疫微环境的时空演进机制及重塑规律。近五年以通讯/第一作者在Nature Medicine（2024、2025）, Lancet Oncology, Science Advances, Cancer Research, Nature Review Clinical Oncology等杂志发表SCI论文，主持国家自然科学基金面上项目、国家自然科学基金重大研究计划集成项目等10项省部级课题，已授权国家发明专利3项，参与编撰专著1部。国际胃癌学会成员（IGCA）、中国抗癌协会青年理事会理事、中国抗癌协会胃癌整合防筛专委会常务委员、北京整合医学学会胃肠外科分会常委、MedComm编委，Fundamental Research青年编委，Chinese Journal of Cancer Research青年编委，中华胃肠外科杂志青年审稿专家，获得中华医学科技奖一等奖（5/15）。入选青年北京学者、北京市医管局“青苗”、北京大学首届临床科学家、北京大学腾云青年科学家等人才计划，2024第四届“人民好医生·金山茶花计划”金奖，研究论文获评“2023-2024年度中国消化道肿瘤领域十佳临床研究”。
发表论文
1.Lin Shen#, Yanqiao Zhang#, Ziyu Li# Xiaotian Zhang#, Xiangyu Gao#, Bo Liu, Yusheng Wang, Yi Ba, Ning Li, Ruixing Zhang, Jingdong Zhang, Ye Chen, Jian Chen, Mingzhu Huang, Yang Fu, Mulin Liu, Zheng Liu , Jun Zhao, Wei Li, Jia Wei, Changzheng Li, Nong Xu, Zengqing Guo, Bangwei Cao, Lian Liu, Peng Nie, Lixin Wan, Lili Sheng, Zhenyang Liu, Yifu He, Kangsheng Gu, Guowu Wu, Weibo Wang, Futong Zhang, Wensheng Qiu, Jun Guo, Jieer Ying, Hongming Pan, Huiting Xu, Yuan Yuan, Yuansong Bai, Zhenghua Wang, Jiye Xu, Xuehong Zhao, Hao Liu, Xizhi Zhang, Wenxiang Dai, Hongyan Xu, Ming Liu, Lin Xie, Yong Tang, Jianying Jin, Xiujuan Qu, Xuefeng Fang, Mingwei Huang, Hao Chen, Zhendong Zheng, Ying Wang, Daqing Wang, Xiaoqin Li, Guohua Yu, Haiyan Liu, Yongjian Zhou, Diansheng Zhong, Shan Zeng, Mafei Kang, Meiqing Wang, Yong Gao, Wenxin Li, Zejun Wang, Minghui Zhang, Jinghua Zhang, Qingshan Li, Shujuan Sun, Aimin Zang, Lizhu Lin, Ming Xie, Zhixiang Zhuang, Tao Zhang, Zhifang Yao, Dongmei Lu, Wei Liu, Mingxiu Hu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Jiajia Zhang, Xiangji Ying, Drew M Pardoll, Jiafu Ji*. First-line cadonilimab plus chemotherapy in HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: a randomized, double-blind, phase 3 trial. Nature Medicine. 2025 Jan 22.
2.Xiaoyong Guo#, Shuangling Luo#, Xiaofeng Wang#, Yingying Cui#, Miaomiao Li#, Zeyu Zhang, Lidan Fu, Caiguang Cao, Xiaojing Shi, Haifeng Liu, Yawei Qu, XiangyuGao*, Huzhen Hua*, Jie Tain*. CD24-Targeted NIR-II Fluorescence Imaging Enables Early Detection of Colorectal Neoplasia. Cancer Research. 2024 Sep 17.
3.Xiangyu Gao#, Ke Ji#, Yongning Jia#, Fei Shan#, Ye Chen#, Nong Xu#, Ziyu Jia#, Tianshu Liu, Nong Yang, Haijun Zhong, Changzheng Li, Zengqing Guo, Qingxia Fan, Xiaoyan Lin, Yan Zhang, Hui Ren, Hongxia Yang, Zhifang Yao, Wei Liu, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Lin Shen*, Ziyu Li*, Jiafu Ji* .Cadonilimab with chemotherapy in unresectable HER2-negative gastric or gastroesophageal junction adenocarcinoma (COMPASSION-04): a phase 1b/2 trial. Nature Medicine. 2024 Jul; 30(7): 1943-1951.
4.Xiangyu Gao#, Nong Xu#, Ziyu Li#, Lin Shen#, Ke Ji#, Zhong Zheng#, Dan Liu, Hanmei Lou, Li Bai, Tianshu Liu, Yunxia Li, Yuzhi Li, Qingxia Fan, Mei Feng, Haijun Zhong, Yi Huang, Ge Lou, Jing Wang, Xiaoyan Lin, Ye Chen, Ruifang An, Changzheng Li, Qi Zhou, Xin Huang, Zengqing Guo, Shubin Wang, Guiling Li, Junwei Fei, Lijing Zhu, Hong Zhu, Xiumin Li, Fenghu Li, Sihai Liao, Qinghua Min, Lei Tang, Fei Shan, Jifang Gong, Yunong Gao, Jun Zhou, Zhihao Lu, Xiaofan Li, Jianjie Li, Hui Ren, Xiaohong Liu, Hongxia Yang, Wenting Li, Weifeng Song, Zhongmin Maxwell Wang, Baiyong Li, Michelle Xia, Xiaohua Wu*, Jiafu Ji*. Safety and antitumour activity of Cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (AK104-201): a multicentre, open-label, phase 1b/2 trial. Lancet Oncology. 2023 Oct; 24(10):1134-1146.
5.Ziyu Li#, Xiangyu Gao#, Xinxin Peng#, Mei-Ju May Chen#, Zhe Li#, Bin Wei, Xianzi Wen, Baoye Wei, Yu Dong, Zhaode Bu, Aiwen Wu, Qi Wu, Lei Tang, Zhongwu Li, Yiqiang Liu, Li Zhang , Shuqin Jia , Lianhai Zhang, Fei Shan, Ji Zhang, Xiaojiang Wu, Xin Ji , Ke Ji, Xiaolong Wu, Jinyao Shi, Xiaofang Xing, Jianmin Wu, Guoqing Lv, Lin Shen, Xuwo Ji, Han Liang*, Jiafu Ji*; Multi-omics Characterization of Molecular Features of Gastric Cancer Correlated with Response to Neoadjuvant Chemotherapy. Science Advances. 2020 Feb 26;6(9):eaay4211.
